Mauricio Castro Herrera
Family Medicine · Arkansas City, KSNPI 1982916565
Payments from drug & device makers
Across 111 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$286
- Abbott$252
- Lilly USA, LLC$247
- AbbVie$170
- Novo Nordisk$157
- Boehringer Ingelheim$107
- plus $657 from 16 others
What the payments were for
- Food & beverage$1,876100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $286 |
| Abbott | 5 | $252 |
| Lilly USA, LLC | 19 | $247 |
| AbbVie(2 entities) | 9 | $170 |
| Novo Nordisk | 9 | $157 |
| Boehringer Ingelheim | 7 | $107 |
| Novartis | 6 | $95 |
| Astellas Pharma US Inc | 6 | $92 |
| Amgen | 6 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $59 |
| Johnson & Johnson | 4 | $59 |
| Pfizer | 4 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Merck | 2 | $25 |
| GSK | 1 | $22 |
| Bayer | 1 | $20 |
| Eisai Inc. | 1 | $18 |
| Infobionic, Inc | 1 | $16 |
| Circassia Inc. | 1 | $15 |
| Insulet Corporation | 1 | $14 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Confirm Rx$118
How this compares
$1,876 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 100 | $99,908 |
| JardianceEmpagliflozin | 67 | $54,408 |
| FarxigaDapagliflozin Propanediol | 69 | $50,861 |
| JanuviaSitagliptin Phosphate | 33 | $30,786 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $27,978 |
| EliquisApixaban | 42 | $27,868 |
| XareltoRivaroxaban | 17 | $14,511 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $9,348 |
| DapagliflozinDapagliflozin Propanediol | 12 | $5,870 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $4,503 |
| EntrestoSacubitril/Valsartan | 14 | $4,103 |
| Lubiprostone | 12 | $3,431 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $3,188 |
| Esomeprazole Magnesium | 22 | $2,850 |
| LantusInsulin Glargine,hum.Rec.Anlog | 18 | $2,595 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $157 | $99,908100 claims |
| Boehringer IngelheimJardiance | $107 | $54,40867 claims |
| AstraZenecaFarxiga | $286 | $50,86169 claims |
| MerckJanuvia | $25 | $30,78633 claims |
| PfizerEliquis | $59 | $27,86842 claims |
| Johnson & JohnsonXarelto | $59 | $14,51117 claims |
| NovartisEntresto | $95 | $4,10314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Arkansas City
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.